In-Depth

The In-Depth page consists of Insight Articles, Commentaries, C-level Q&As, Discussion Group Reports, and Survey Reports.

Discussion Group Report
Nazneen Dewji, President and CEO of Cenna Biosciences leads a discussion on the strategies to overcome the challenges ‘Oral Delivery of Peptides’.
Edited by Tia Byer |
24 June 2022
Peptides
Insight Article
Key opinion leaders share their thoughts on the prospect of effector cell redirection and cell engagers at Biologics UK: In-Person 2022.
Edited by Tia Byer |
07 June 2022
Bispecifics
Commentary
In this Commentary article, we explore how innovative technologies like expression tags could help to overcome challenges associated with recombinant peptide production. The potential for recombinant production to slash manufacturing costs has made it a focal area of research for companies such as Boehringer Ingelheim.
17 May 2022
Peptides
Insight Article
UCB, Bicycle Therapeutics, and Sanofi share their latest findings in Peptide discovery at Biologics UK 2022.
Edited by Tia Byer |
10 May 2022
Peptides
Discussion Group Report
Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our April Discussion Group addressing ‘Accelerating Antibody Engineering With AI/ML & Advanced Computational Tools and Technologies’ brought together an exclusive panel of key opinion leaders to address the market’s growth and future outlook.
Edited by Tia Byer |
05 May 2022
Proteins & Antibodies
Insight Article
As market leaders in the biologics field, there is no sign of demand for antibody-based therapies slowing down any time soon. With exclusive insights from the CRUK-AstraZeneca Antibody Alliance Laboratory, we look towards the future of antibody discovery and optimisation.
Edited by Tia Byer |
25 April 2022
Proteins & Antibodies
Discussion Group Report
Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our March Discussion Group addressing ‘Sustainable Synthesis of Therapeutic Oligonucleotides’ brought together an exclusive panel of key opinion leaders to address the market’s growth and future outlook.
Edited by Tia Byer |
21 April 2022
Oligonucleotides
Commentary
While membrane proteins are inherently unstable and challenging to work with, Salipro Biotech are focusing on the stabilisation of challenging protein targets for a variety of downstream applications. This Commentary article explores how Salipro’s platform technology enables new opportunities for drug development.
20 April 2022
Proteins & Antibodies
Discussion Group Report
Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our February Discussion Group addressing ‘T Cell Engagement and Redirection – Strategies, Methods, and T Cell Design’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.
Edited by Tia Byer |
11 March 2022
Proteins & Antibodies
Insight Article
With efficacy, safety, and targetability being the top three challenges facing the nucleotide-based therapeutic industry today, will oligo-based therapies fulfil their potential as a clinical modality?
Edited by Tia Byer |
03 March 2022
Oligonucleotides
Commentary
Oligonucleotides are fast becoming a globally recognised form of therapeutic treatment. But how easy is it to analyse them? Director of AstraZeneca, Tomas Leek takes us through the analytic challenges of the early-stage oligonucleotide characterisation.
Edited by Tia Byer |
01 March 2022
Oligonucleotides
Insight Article
Stimulating T cells using bispecific antibody immunotherapies can lead to transformational clinical benefits for cancer patients. So how exactly is the industry addressing the need for targeted T cell-based immunotherapies?
Edited by Tia Byer |
28 February 2022
Bispecifics
Discussion Group Report
Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our January Discussion Group addressing ‘Peptides Green Chemistry Strategies and Methods’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.
Edited by Tia Byer |
25 February 2022
Peptides
Discussion Group Report
Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our November Discussion Group addressing ‘Bi-and Multi-Specific Antibodies - Formats, Applications, and Paths to the Clinic’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.
Edited by Tia Byer |
09 February 2022
Bispecifics
Commentary
The joint development project by Alligator Bioscience and Aptevo Therapeutics, ALG.APV-527, shows potential in targeting solid tumours
Edited by Tom Cohen |
17 January 2022
Bispecifics
Insight Article
In this Insight Article, we explore the future possibilities, challenges, and solutions in peptide purification and the delivery of precision medicine for immunotherapy.
Edited by Tia Byer |
14 January 2022
Peptides
Insight Article
What are monoclonal antibodies, and their therapeutic opportunity for targeting complex membrane proteins? This Insight Article covers the latest industry insights and interviews a senior representative from the pharmaceutical industry on addressing specific challenges for antibody discovery.
Edited by Tia Byer |
23 December 2021
Proteins & Antibodies
Commentary
Christine Rothe, Vice President of Early-Stage-Project Leadership and Data Science at Pieris Pharmaceuticals, presents a case study on Anticalin-antibody fusions for IO.
Edited by Tia Byer |
08 December 2021
Proteins & Antibodies
Discussion Group Report
Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our October Discussion Group addressing ‘Analytical Method Development for Biotherapeutics’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.
Edited by Tia Byer |
09 November 2021
Biologics Analysis
Commentary
Can biparatopic antibody-drug conjugates enhance cellular trafficking to cancerous tumours? William Olson of Regeneron finds out.
Edited by Tia Byer |
01 November 2021
Proteins & Antibodies
Advertisement

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.

Member Community Login